Quantum Genomics - Firibastat misses endpoints in Phase III
Quantum Genomics has announced that results from the Phase III FRESH study, investigating the use of firibastat in treatment-resistant hypertension...
590 Views
Quantum Genomics - Steady sailing as FRESH readout approaches
Quantum Genomics’ H122 results showed the company is on steady footing as it approaches a key inflection point. Top-line data from the Phase III...
677 Views
Quantum Genomics - A fresh take on cardiovascular medicine
Quantum Genomics is focused on the development of new classes of cardiovascular medicines. Firibastat, the company’s lead clinical asset, is in...
666 Views
Quantum Genomics - Termination of coverage
Edison Investment Research is terminating coverage on PIERER Mobility (PMAG), Allarity Therapeutics (ALLR), WANdisco (WAND), Quantum Genomics...
463 Views
Quantum Genomics - Phase IIb QUORUM results
Quantum Genomics has reported the results of the Phase IIb QUORUM study at the European Society of Cardiology. Unfortunately, the primary endpoint...
1k Views